相似文献
1
Tumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells.
Transl Oncogenomics. 2007 May 3;2:43-7. Print 2007.
2
Expression of the active Notch1 decreases MTC tumor growth in vivo.
J Surg Res. 2011 Nov;171(1):23-7. doi: 10.1016/j.jss.2011.03.035. Epub 2011 Apr 13.
3
Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells.
J Biol Chem. 2006 Dec 29;281(52):39819-30. doi: 10.1074/jbc.M603578200. Epub 2006 Nov 7.
4
Medullary thyroid cancer: the functions of raf-1 and human achaete-scute homologue-1.
Thyroid. 2005 Jun;15(6):511-21. doi: 10.1089/thy.2005.15.511.
5
Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells.
Ann Surg. 2008 Jun;247(6):1036-40. doi: 10.1097/SLA.0b013e3181758d0e.
6
Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer.
Am J Surg. 2010 Mar;199(3):315-8; discussion 318. doi: 10.1016/j.amjsurg.2009.08.034.
7
The role of human achaete-scute homolog-1 in medullary thyroid cancer cells.
Surgery. 2003 Dec;134(6):866-71; discussion 871-3. doi: 10.1016/s0039-6060(03)00418-5.
8
Differentiation of medullary thyroid cancer by C-Raf-1 silences expression of the neural transcription factor human achaete-scute homolog-1.
Surgery. 1996 Aug;120(2):168-72; discussion 173. doi: 10.1016/s0039-6060(96)80284-4.
9
Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways.
Surgery. 2007 Dec;142(6):959-64; discussion 959-64. doi: 10.1016/j.surg.2007.09.020.
10
Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.
Ann Surg Oncol. 2008 Sep;15(9):2600-5. doi: 10.1245/s10434-008-0006-z. Epub 2008 Jun 18.
引用本文的文献
1
Multi-targeted approach in the treatment of thyroid cancer.
Minerva Chir. 2010 Feb;65(1):59-69.
2
Multi-targeted approach in the treatment of thyroid cancer.
Ther Clin Risk Manag. 2008 Oct;4(5):935-47. doi: 10.2147/tcrm.s3062.
3
Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors.
Curr Opin Investig Drugs. 2008 Jun;9(6):576-82.
本文引用的文献
1
Human achaete-scute homolog-1 is highly expressed in a subset of neuroendocrine tumors.
Oncol Rep. 1997 Jul-Aug;4(4):775-8. doi: 10.3892/or.4.4.775.
2
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
Mol Cancer Ther. 2007 Mar;6(3):1151-8. doi: 10.1158/1535-7163.MCT-06-0665.
3
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
Surgery. 2006 Dec;140(6):1009-14; discussion 1014-5. doi: 10.1016/j.surg.2006.06.040. Epub 2006 Nov 1.
4
Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells.
J Biol Chem. 2006 Dec 29;281(52):39819-30. doi: 10.1074/jbc.M603578200. Epub 2006 Nov 7.
5
Notch signalling: a simple pathway becomes complex.
Nat Rev Mol Cell Biol. 2006 Sep;7(9):678-89. doi: 10.1038/nrm2009.
6
Carcinoid tumors.
Surg Oncol Clin N Am. 2006 Jul;15(3):463-78. doi: 10.1016/j.soc.2006.05.002.
7
The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?
Anticancer Drugs. 2006 Feb;17(2):139-42. doi: 10.1097/00001813-200602000-00004.
8
Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells.
Surgery. 2005 Dec;138(6):1137-42; discussion 1142. doi: 10.1016/j.surg.2005.05.027.
9
Treatment of advanced carcinoid tumors.
Curr Opin Oncol. 2006 Jan;18(1):9-15. doi: 10.1097/01.cco.0000198018.53606.62.
10
Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells.
Am J Physiol Gastrointest Liver Physiol. 2005 Oct;289(4):G636-42. doi: 10.1152/ajpgi.00146.2005.
Zotero 插件